Search Results

December 9, 2013

Janssen, the Pharmaceutical Companies of Johnson & Johnson, Announces First-of-its-Kind Drug Donation Program for HIV Treatment-Experienced Children

Sub-Saharan African Ministries of Health Invited to Submit Expression of Interest to Participate in New EffortDonation Program to be Part of Broader Initiative to Raise Awareness and Action

Innovative Medicine

December 9, 2013

New VELCADE® Data Highlight Treatment’s Versatility And Its Continued Role As A Backbone Of Multiple Myeloma Therapy

Studies affirm benefits of VELCADE (bortezomib) therapy regarding survival, disease progression, safety and quality of life in multiple myeloma, in both monotherapy and combination therapy

Innovative Medicine

December 9, 2013

Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65

Encouraging Data from a Phase 1b/2, Open-label, Multicenter Study

Innovative Medicine

December 5, 2013

Janssen Pharmaceutica NV Extends Commitment to Global Mental Health Scholarships as Part of Its Healthy Minds Programme

Funding to British schools continues meaningful aid for future leaders in mental health research, policy and practice

Innovative Medicine

December 3, 2013

New Data at American Society of Hematology (ASH) Annual Meeting Will Offer Important Insights into Safe and Efficacious Use of XARELTO®

XARELTO® is the Most Prescribed Novel Oral Anticoagulant in the U.S. Market Today

Innovative Medicine

November 22, 2013

OLYSIO™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C

OLYSIO™is the first once-daily protease inhibitor approved for the treatment of chronic hepatitis C in a combination antiviral regimen for adults with compensated liver disease

Innovative Medicine

November 22, 2013

INVOKANA™ (canagliflozin) Approved In The European Union For Treatment Of Adults With Type 2 Diabetes[1]

Innovative Medicine

November 19, 2013

Janssen Oncology Data to be Presented at 2013 American Society of Hematology (ASH) Annual Meeting

Findings Highlight Company’s Growing Hematologic Area of Focus, Including Ibrutinib, Siltuximab and Daratumumab

Innovative Medicine

November 13, 2013

IMBRUVICA™ (ibrutinib) Capsules Now Approved in the U.S. for Mantle Cell Lymphoma Patients Who Have Received at Least One Prior Therapy

Single-agent oral therapy is one of the first medications to be approved via the U.S. Food and Drug Administration’s Breakthrough Therapy Designation Pathway

Innovative Medicine

November 4, 2013

Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naïve and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine